Systems and methods for treating coronavirus
US-2024131003-A1 · Apr 25, 2024 · US
US12306191B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12306191-B2 |
| Application number | US-201916982500-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 21, 2019 |
| Priority date | Mar 21, 2018 |
| Publication date | May 20, 2025 |
| Grant date | May 20, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a composition for diagnosis of degenerative neurological diseases and, more specifically, to a composition for diagnosis of degenerative neurological diseases, comprising an agent for measuring the level of acetylation of COX2. According to the present invention, since acetylation of COX2 in degenerative neurological diseases is significantly reduced, whether COX2 is acetylated may be utilized as a diagnostic marker for degenerative neurological diseases, and it is possible to diagnose degenerative neurological diseases more rapidly and accurately by using same.
Opening claim text (preview).
What is claimed is: 1. A method of treatment, comprising: (a) providing a biological sample from a patient; (b) measuring the level of acetylation of COX2 (cyclooxygenase-2) in the sample; (c) identifying the sample as having a level of acetylation of the COX2 that is lower than that of a normal control sample; and (d) treating the patient for a degenerative neurological disease using a COX2 acetylating agent based on the results of step (c). 2. The method of claim 1 , wherein the method for measuring the level of acetylation of COX2 is at least one selected from the group consisting of autoradiography, liquid scintillation counting, molecular weight assay, liquid chromatographic mass assay, Western blot, ELISA, radioimmunoassay, radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunofluorescence staining, immunohistochemical staining, immunoprecipitation assay, complement fixation assay, FACS, and protein chip. 3. The method of claim 1 , wherein the sample is selected from the group consisting of blood, blood cells, brain tissue, nerve cells, cerebrospinal fluid, saliva, nasal fluid, sputum, synovial fluid, amniotic fluid, ascites, cervical or vaginal secretions, and urine.
acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13) · CPC title
for enzymes or isoenzymes · CPC title
acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation · CPC title
for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title
of a carboxylic acid with an aminoalcohol, e.g. ceramides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.